Previous 10 | Next 10 |
2023-10-10 12:19:25 ET What has been an otherwise bullish week was originally expected to become extremely volatile heading into mid-week. While things appear to be business as usual for a stock market rally could change quickly starting Wednesday, October 11th. What’s going on in th...
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI). Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and...
Median overall survival of 13.6 months with BXCL701 + KEYTRUDA ® ( pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (CPI) in late-line refractory patients in separate, Phase 2 trial 1 56% of studied patients alive at one year foll...
2023-10-05 08:16:47 ET More on BioXcel Therapeutics, Lithium Americas Corp., etc. Lithium Americas (Argentina): An Outrageously Undervalued Lithium Company BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties BioXcel's Struggles: From FDA Issues To F...
2023-10-04 15:40:17 ET More on BioXcel Therapeutics BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties BioXcel's Struggles: From FDA Issues To Financial Instability BioXcel Therapeutics, Inc. (BTAI) Q2 2023 Earnings Call Transcript Mizuho c...
2023-10-04 13:55:53 ET Gainers: Vivos Therapeutics ( VVOS ) +111% . Nuvalent ( NUVL ) +30% . Spectral AI ( MDAI ) +27% . Gaucho Group Holdings ( VINO ) +25% . Gritstone Bio ( GRTS ) +19% . BioXcel Therapeutics ( BTAI ) ...
Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI ™ market exclusivity through receipt of two Notices of Allowance NEW HAVEN, Conn., Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, In...
2023-10-02 02:47:57 ET Summary FDA investigation into BioXcel's TRANQUILITY II study raises concerns about data integrity and management of the trial, impacting stock uncertainties. FDA's Type C meeting on November 8, 2023, will determine if BTAI can pursue regulatory approval bas...
2023-09-28 17:35:12 ET Shares of BioXcel (NASDAQ: BTAI) were down 14.4% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence . The biotech company's shares closed at $2.91 last week, then fell to a new 52-week low of $2.48 on ...
Radnor, Pennsylvania--(Newsfile Corp. - August 24, 2023) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI). The action charges BioXcel wi...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...